Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: A rapidly evolving problem in Italy, November 2013 to April 2014

Eurosurveillance

Volumn 19, Issue 42, 2014, Pages

  Monaco, M ^a   Giani, T ^b   Raffone, M ^a,c   Arena, F ^b   Garcia Fernandez, A ^a   Pollini, S ^b   Grundmann, H ^d   Pantosti, A ^a   Rossolini, G M ^b,e,f  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY OF FLORENCE   (Italy)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; DISEASE SURVEILLANCE; ENDEMIC DISEASE; EUROPE; FEMALE; HUMAN; ITALY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; POLYMERASE CHAIN REACTION; SENTINEL SURVEILLANCE;

EID: 84908528845     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.42.20939     Document Type: Article

References (20)

1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682-707. http://dx.doi.org/10.1128/CMR.05035-11
2. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791-8. http://dx.doi.org/10.3201/eid1710.110655
3. Glasner C, Albiger B, Buist G, Tambić Andrasević A, Canton R, Carmeli Y, et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill. 2013;18(28): 20525.
4. Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18(5):413-31. http://dx.doi.org/10.1111/j.1469-0691.2012.03821.x
5. European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC. [Accessed 21 Oct 2014]. Available from: http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx
6. Sisto A, D’ Ancona F, Meledandri M, Pantosti A, Rossolini GM, Raglio A, et al. Carbapenem non-susceptible Klebsiella pneumoniae from Micronet network hospitals, Italy, 2009 to 2012. Euro Surveill. 2012;17(33): 20247.
7. Giani T, Pini B, Arena F, Conte V, Bracco S, Migliavacca R, et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill. 2013;18(22): 20489.
8. Petrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11(2):159-77. http://dx.doi.org/10.1586/eri.12.162
9. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20(9):862-72. http://dx.doi.org/10.1111/1469-0691.12697
10. European Centre for Disease Prevention and Control (ECDC). Carbapenemase-producing bacteria in Europe: interim results from the European Survey on carbapenemase-producing Enterobacteriaceae (EuSCAPE) project. Stockholm: ECDC; 2013.
11. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved 255 Standard. Eighth Edition. Wayne, PA: CLSI; document M7-A9.
12. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. Växjö: EUCAST. [Accessed 21 Oct 2014]. Available from: http://www.eucast.org/clinical_breakpoints/
13. Mezzatesta ML, Gona F, Caio C, Petrolito V, Sciortino D, Sciacca A, et al. Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals. Clin Microbiol Infect. 2011;17(9):1444-7.
14. Ah YM, Kim AJ., Lee JY. Colistin resistance in Klebsiella pneumoniae. Int J Antimicrob Agents. 2014;44(1):8-15.http://dx.doi.org/10.1016/j.ijantimicag.2014.02.016
15. European Centre for Disease Prevention and Control (ECDC). Consumption of antimicrobials of Antibacterials For Systemic Use (ATC group J01) in the community (primary care sector) in Europe, Reporting year 2012. Stockholm: ECDC. [Accessed 21 Oct 2014]. Available from: http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/esac-net-database/Pages/Antimicrobial-consumption-rates-by-country.aspx
16. Ministero della Salute. Circolare ‘Sorveglianza e controllo delle infezioni da batteri produttori di carbapenemasi (CPE)’. [Circular letter ‘Surveillance and control of infections due to carbapenemase-producing bacteria (CPE)]. Rome: Ministero della Salute; Feb 2014. Italian. [Accessed 21 Oct 2014]. Available from: http://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=0&codLeg=45499&parte=1%20 &serie
17. Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill. 2010;15(46): 19711.
18. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis. 2011;52(7):848-55. http://dx.doi.org/10.1093/cid/cir025
19. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect. 2012;18(5):439-48. http://dx.doi.org/10.1111/j.1469-0691.2012.03823.x
20. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(Suppl 1):1-55. http://dx.doi.org/10.1111/1469-0691.12427